Canakinumab for systemic-onset juvenile idiopathic arthritis/Still’s disease—effectiveness and safety data from the BiKeR registry
ABSTRACT: Objectives: In Germany, canakinumab is approved for the treatment of refractory systemic juvenile idiopathic arthritis (sJIA)/Still’s disease. This study assesses the experience of sJIA/Still’s disease patients treated with canakinumab in clinical practice. Methods: Data of 79 sJIA/Still’...
Bewaard in:
| Hoofdauteurs: | , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Elsevier
2026-06-01
|
| Reeks: | EULAR Rheumatology Open |
| Online toegang: | http://www.sciencedirect.com/science/article/pii/S3050708125001107 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|